Search Result

Results for "

NSG

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Acetyl-CoA synthetase (1) Akt (2) Anaplastic lymphoma kinase (ALK) (1) Androgen Receptor (1) Apoptosis (13) Atg8/LC3 (1) ATM/ATR (1) Aurora Kinase (1) Autophagy (1) Caspase (3) CD19 (1) CD20 (1) CD28 (1) CD3 (2) CD47 (1) CD6 (1) CDK (2) Checkpoint Kinase (Chk) (1) Dihydroorotate Dehydrogenase (1) DNA Methyltransferase (1) DNA/RNA Synthesis (1) E3 Ligase Ligand-Linker Conjugates (1) Endogenous Metabolite (1) Epigenetic Reader Domain (1) Fat Mass and Obesity-associated Protein (FTO) (1) Fc Receptor (FcR) (1) FLT3 (2) HIF/HIF Prolyl-Hydroxylase (1) Histone Acetyltransferase (1) Histone Methyltransferase (3) Interleukin Related (1) Itk (1) JAK (2) LAG-3 (1) MAP4K (1) MDM-2/p53 (1) MicroRNA (1) mTOR (1) Necroptosis (1) NF-κB (1) Parasite (5) PARP (2) PD-1/PD-L1 (2) PDI (2) PI3K (3) PI4K (2) Potassium Channel (1) PROTACs (6) RIP kinase (2) Small Interfering RNA (siRNA) (2) STAT (2) TGF-beta/Smad (1) TGF-β Receptor (1) Transmembrane Glycoprotein (1) YAP (1)
By Research Areas:	Cancer (38) Infection (7) Inflammation/Immunology (8) Metabolic Disease (2)
Click Chemistry:	Alkynes (1)
Oligonucleotides:	Human Pre-designed siRNA Sets (2) siRNAs (2)

Inhibitors & Agonists

Inhibitory Antibodies

Click Chemistry

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-157941

ART0380	ATM/ATR Checkpoint Kinase (Chk) DNA/RNA Synthesis	Cancer
ART0380 is a potent, selective and orally active ATR kinase inhibitor. ART0380 potently inhibits human ATR-ATRIP complex with an IC₅₀ of 51.7 nM. ART0380 binds the ATP pocket of the ATR-ATRIP complex, blocks ATR-dependent Chk1 serine 345 phosphorylation, and induces cell cycle disorder and DNA damage. ART0380 demonstrates potent and selective antitumor activity in preclinical models with varying types of ataxia-telangiectasia mutated (ATM) gene aberrancy. ART0380 can be used for the research of cancer, such as colorectal cancer and prostate cancer .

HY-145765

JQAD1 2 Publications Verification	PROTACs Histone Acetyltransferase Apoptosis Caspase PARP	Cancer
JQAD1 is a CRBN-dependent PROTAC that selectively targets EP300 for degradation. JQAD1 suppresses EP300 expression and the H3K27ac modification. JQAD1 induces apoptosis. JQAD1 can be used in research of cancer .

HY-P99222

Teplizumab MGA-031; PRV-031	CD3	Metabolic Disease
Teplizumab (MGA-031) is a Fc receptor non-binding anti-human CD3 monoclonal antibody. Teplizumab reduces the loss of beta-cell function. Teplizumab can be used in the research of type 1 diabetes .

HY-175282

ASX-173	Apoptosis Caspase CDK PARP Akt Autophagy Atg8/LC3	Cancer
ASX-173 is an orally active inhibitor of asparagine synthetase (ASNS) (IC₅₀ = 0.113 μM, K_i = 0.4 nM). ASX-173 enhances the anticancer activity of L-asparaginase (ASNase) (HY-P1923). ASX-173 disrupts nucleotide synthesis and induces leukemia cell cycle arrest, apoptosis and autophagy in leukemia cells in combination with ASNase. ASX-173 slows the growth of OCI-AML2 xenografts in combination with ASNase. ASX-173 is indicated for the study of acute lymphoblastic leukemia, acute myeloid leukemia, colorectal cancer, and other cancers .

HY-P99199

Foralumab NI-0401	CD3	Inflammation/Immunology
Foralumab (NI-0401) is a potent, orally active human monoclonal antibody targeting the CD3. Foralumab modulates immune responses by human cells in NSG mice that were reconstituted with human hematopoietic stem cells .

HY-174143

EXO1-IN-1	Apoptosis	Cancer
EXO1-IN-1 is a human exonuclease 1 (EXO1) inhibitor (IC₅₀ = 15.7 μM). EXO1-IN-1 inhibits DNA end resection, promotes the accumulation of DNA double-strand breaks, and triggers S-phase polyamylation. EXO1-IN-1 induces apoptosis (Apoptosis) in BRCA1-deficient breast cancer cells. EXO1-IN-1 suppresses the growth of BRCA1-deficient breast cancer xenografts. EXO1-IN-1 can be used in research related to BRCA1-deficient breast cancer .

HY-151902

SJ988497	PROTACs JAK	Cancer
SJ988497 is a PROTAC JAK2 degrader. SJ988497 potently inhibits CRLF2-rearranged (CRLF2r) cell proliferation and degrades the CRBN neosubstrate GSPT1. SJ988497 consists of a Ruxolitinib (HY-50856) derivative, linker, and CRBN ligand Pomalidomide. SJ988497 can be used in the research of acute lymphoblastic leukemia (ALL) .

HY-168016

PROTAC YAP degrader-1	PROTACs YAP	Cancer
PROTAC YAP degrader-1 is a VHL-recruiting PROTAC degrader (DC₅₀=8.2 μM) and antiproliferative agent that targets YAP. PROTAC YAP degrader-1 recruits the E3 ligase VHL and binds to VHL to form a ternary complex containing YAP. PROTAC YAP degrader-1 inhibits the nuclear localization of YAP in cancer cells, reduces YAP/TEAD-mediated transcription, and induces TAZ protein degradation. PROTAC YAP degrader-1 reduces the oncogenic activity of YAP and exerts antiproliferative effects in the Huh7 xenograft mouse model. PROTAC YAP degrader-1 can be used for the research of hepatocellular carcinoma and mesothelioma .

HY-174979

Dac590	Fat Mass and Obesity-associated Protein (FTO) Apoptosis	Inflammation/Immunology Cancer
Dac590 is an orally active and selective obesity-associated protein (FTO) inhibitor with an IC₅₀ of 6.06 nM. Dac590 shows highly selective over ALKBH5 and ALKBH3. Dac590 suppresses oncogenic FTO signaling, induces myeloid differentiation, G1-phase cell cycle arrest, and apoptosis in acute myeloid leukemia (AML) cells. Dac590 inhibits xenograft tumor growth and prolongs survival in acute myeloid leukemia mouse models with no observed toxicity. Dac590 can be used for the research of AML .

HY-122895

E64FC26 2 Publications Verification	Apoptosis PDI	Cancer
E64FC26 is a potent pan-inhibitor of the protein disulfide isomerase (PDI) family, with IC₅₀s of 1.9, 20.9, 25.9, 16.3, and 25.4 μM against PDIA1, PDIA3, PDIA4, TXNDC5, and PDIA6, respectively. E64FC26 shows anti-myeloma activity .

HY-143889

Senexin C	CDK	Cancer
Senexin C is a selective and orally active CDK8/19 inhibitor. Senexin C shows a strong tumor-enrichment pharmacokinetic (PK) profile and tumor-pharmacodynamic (PD) marker responses. Senexin C inhibits the growth of MV4-11 leukemia cells with good tolerability .

HY-P99252

Itolizumab Anti-Human CD6 Recombinant Antibody	CD6	Infection Inflammation/Immunology
Itolizumab (Anti-Human CD6 Recombinant Antibody) is a humanized recombinant anti-CD6 monoclonal antibody (MAb) targeting the extracellular SRCR distal domain 1 of CD6. Itolizumab reduces T-cell proliferation and inhibits the production of pro-inflammatory cytokines, such as INF-γ, TNFα and IL-6. Itolizumab can be used in the research of psoriasis, rheumatoid arthritis (RA), COVID-19 .

HY-P99884

Sasanlimab PF-06801591	PD-1/PD-L1	Inflammation/Immunology Cancer
Sasanlimab is a humanized IgG4 isotype anti-PD-1 antibody. Sasanlimab blocks PD-1 interaction with PD-L1/PD-L2, reverses PD-1-mediated inhibitory T-cell signaling, augments T-cell proliferation and cytokine production. Sasanlimab inhibits colon adenocarcinoma tumor growth, and accelerates graft-versus-host disease incidence via enhanced T-cell activity. Sasanlimab can be used for the research of cancer, such as bladder cancer and colon adenocarcinoma .

HY-P2989

Pyruvate carboxylase	Endogenous Metabolite	Metabolic Disease Cancer
Pyruvate carboxylase is a key mitochondrial anaplerotic enzyme that catalyzes the conversion of pyruvate to oxaloacetate. Pyruvate carboxylase not only maintains tricarboxylic acid cycle activity and redox homeostasis, but also drives hepatic gluconeogenesis and fatty acid synthesis. The activity of Pyruvate carboxylase is upregulated in insulin-resistant states, exacerbating hepatic glucose production. Pyruvate carboxylase also shows significantly enhanced expression in early-stage non-small cell lung cancer (NSCLC). Pyruvate carboxylase promotes tumor proliferation by supporting nucleotide and lipid synthesis, and its functional deficiency cannot be compensated by glutaminolysis. Pyruvate carboxylase can be used in the research of prediabetes type 2 and NSCLC .

HY-115581A

Thymidine 3',5'-diphosphate tetrasodium Deoxythymidine 3′,5′-diphosphate tetrasodium; pdTp tetrasodium	Apoptosis MicroRNA	Cancer
Thymidine 3',5'-diphosphate (Deoxythymidine 3′,5′-diphosphate) tetrasodium is a selective inhibitor of staphylococcal nuclease and tudor domain containing 1 (SND1, the MicroRNA regulatory complex RISC subunit) and [3,5- ²H₂] tyrosyl nuclease. Thymidine 3',5'-diphosphate tetrasodium has anti-tumor activity and can also be used as a catalyst in biochemical reactions .

HY-109179

Itacnosertib TP-0184	JAK Anaplastic lymphoma kinase (ALK) FLT3 STAT PI3K Akt mTOR TGF-beta/Smad TGF-β Receptor	Cancer
Itacnosertib (TP-0184) is the inhibitor for FLT3, ACVR1 (ALK2, IC₅₀=8 nM) and JAK2 (IC₅₀=8540 nM). Itacnosertib exhibits anti-leukemic activity .

HY-175370

PROTAC RIPK1 Degrader-1	PROTACs RIP kinase	Cancer
PROTAC RIPK1 Degrader-1 is a selective RIPK1 PROTAC degrader. PROTAC RIPK1 Degrader-1 degrades RIPK1 in multiple cancer cell lines (e.g., A375, B16F10 cells). PROTAC RIPK1 Degrader-1 enhances the anti-cancer effect of radiotherapy in syngeneic and humanized mouse models. PROTAC RIPK1 Degrader-1 can be used to study cancers such as melanoma. (Pink: RIPK1-ligand-2: HY-175371, Blue: (S,R,S)-AHPC-Me: HY-112078, Pink + Black: RIPK1 ligand-Linker Conjugate-1: HY-175374, Black: Bispiperidin-piperazin-acetater: HY-175373) .

HY-122895A

(E/Z)-E64FC26	Apoptosis PDI	Cancer
(E/Z)-E64FC26 is a mixture complex of E-E64FC26 and Z-E64FC26. E64FC26 (E-E64FC26) is a potent pan-inhibitor of the protein disulfide isomerase (PDI) family, with IC₅₀s of 1.9, 20.9, 25.9, 16.3, and 25.4 μM against PDIA1, PDIA3, PDIA4, TXNDC5, and PDIA6. E64FC26 shows anti-myeloma activity .

HY-168022

CAM2602 1 Publications Verification	Aurora Kinase	Cancer
CAM2602 is an orally active Aurora A-TPX2 protein−protein interaction inhibitor with a human K_d of 19 nM for Aurora A. CAM2602 increases the proportion of PH3 positive cells while reducing P-T288 Aurora A levels. CAM2602 arrests tumor xenograft growth in mice. CAM2602 can be used for the research of cancer, such as acute T cell leukemia .

HY-P991176

RG-6333 RO7443904	CD19 CD28	Cancer
RG-6333 is a bispecific agonist targeting CD19 and CD28. RG-6333 specifically recognizes and binds to the CD19 antigen on the surface of B-cell malignancies to locate tumor cells. RG-6333 activates T cells by binding to CD28, overcoming activation barriers to enhance anti-tumor immunity. RG-6333 can be used in the study of relapsed/refractory non-Hodgkin's lymphoma. The recommended isotype control is human IgG1 kappa, isotype control (HY-P99001) .

HY-P99354

Bavunalimab Anti-Human CTLA4xLAG3; XmAb-22841; Pavunalimab	LAG-3	Inflammation/Immunology Cancer
Bavunalimab (Anti-Human CTLA4xLAG3) is a bispecific human anti-CTLA-4/LAG-3 monoclonal antibody. Bavunalimab activates T cells in NSG mice. Bavunalimab can be used for the research of cancer .

HY-178775

PI4K-IN-3	PI4K Parasite MAP4K PI3K	Infection
PI4K-IN-3 (Compound 27) is an orally active PI4K inhibitor with an IC₅₀ of 1.9  nM for Plasmodium vivax PI4K. PI4K-IN-3 has no hERG channel inhibition and mammalian cytotoxicity. PI4K-IN-3 has significant selectivity against the human MINK1 and MAP4K4 kinases but with low selectivity against human PI3Kα and PI4Kβ. PI4K-IN-3 has potent antimalarial activity and significantly reduces parasitaemia in NSG mice mouse models of Plasmodium falciparum malaria .

HY-170453

iHAC	Epigenetic Reader Domain	Cancer
iHAC is an inhibitor HSP90-anchoring chimera, that covalently binds BRD4 ligand (+)-JQ-1 to HSP90, and inhibits the proliferation of cancer cells. iHAC activates the anti-tumor immune response, inhibits the recurrence and metastasis of 4T1 breast cancer in mouse models .

HY-RS09593

NSG1 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
NSG1 Human Pre-designed siRNA Set A contains three designed siRNAs for NSG1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

NSG1 Human Pre-designed siRNA Set A NSG1 Human Pre-designed siRNA Set A

HY-RS09594

NSG2 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
NSG2 Human Pre-designed siRNA Set A contains three designed siRNAs for NSG2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

NSG2 Human Pre-designed siRNA Set A NSG2 Human Pre-designed siRNA Set A

HY-162343

PD-1/PD-L1-IN-41	PD-1/PD-L1	Inflammation/Immunology Cancer
PD-1/ PD-L1-in-41 (Compound 5c) is a PD-L1 and PD-1 inhibitor with IC₅₀ value of 10.2 nM .

HY-185206

BSJ-05-037	PROTACs Itk NF-κB	Cancer
BSJ-05-037 is an ITK PROTAC degrader that effectively targets and degrades ITK in T-cell lymphoma cell lines. BSJ-05-037 blocks the activation of the NF-κB/GATA-3 signaling pathway, inhibits PLCγ1 phosphorylation, and reduces the proliferative capacity of T-cell lymphoma cells. BSJ-05-037 enhances the sensitivity of T-cell lymphoma cells to chemotherapy. In mouse models of T-cell lymphoma, BSJ-05-037 induces ITK degradation, reduces GATA-3 expression, decreases tumor volume, and reverses chemotherapy resistance. BSJ-05-037 is applicable to research related to T-cell lymphoma .

HY-148178

MMV688533	Parasite	Infection
MMV688533 is an antimalarial agent. MMV688533 interferes with intracellular trafficking, lipid utilization, and endocytosis pathways in Plasmodium falciparum. MMV688533 rapidly kills asexual blood-stage Plasmodium falciparum and Plasmodium vivax parasites in vitro and reduces parasitemia in a Plasmodium falciparum NSG mouse model. MMV688533 can be used for the research of malaria .

HY-172953

Insecticidal agent 24	Parasite	Infection
Insecticidal agent 24 is an orally active pyridylspiroindoline frontrunner. Insecticidal agent 24 has antiplasmodial activity (Pf NF54 IC₅₀: 0.08 μM). Insecticidal agent 24 inhibits hERG activity (IC₅₀: 6.5 μM). Insecticidal agent 24 reduces parasitemia in a humanized immunodeficient NSG mouse Plasmodium falciparum infection model .

HY-163765

Antimalarial agent 41	PI4K Potassium Channel	Infection
Antimalarial agent 41 (Compound 17) exhibits antimalarial activity, which inhibits Plasmodium falciparum with an IC₅₀ of 40 nM (NF54 strain) and 76 nM (K1 strain). Antimalarial agent 41 is an inhibitor for P. falciparum phosphatidylinositol-4-kinase β (Pf PI4K) and hERG channel, with an IC₅₀ of 53 nM and 3 μM. Antimalarial agent 41 exhibits cytotoxicity to CHO cells with an IC₅₀ of 34 μM. Antimalarial agent 41 ameliorates the malaria infection and exhibits good pharmacokinetic characters in mouse models .

HY-115581

Thymidine 3',5'-disphosphate Deoxythymidine 3′,5′-diphosphate; pdTp	Apoptosis	Cancer
Thymidine 3',5'-disphosphate (Deoxythymidine 3′,5′-diphosphate; pdTp) is a selective small molecule inhibitor of staphylococcal nuclease and tudor domain containing 1 (SND1, the miRNA regulatory complex RISC subunit) and inhibits SND1 activity. Thymidine 3',5'-disphosphate exhibits anti-tumor efficacy in vivo .

HY-176223

Antimalarial agent 51	Parasite	Infection
Antimalarial agent 51 (Compound 2) is an orally active antimalarial compound. Antimalarial agent 51 blocks nutrient uptake by Plasmodium by inhibiting the plasmodium surface anion channel (PSAC). Antimalarial agent 51 significantly inhibits the growth of Plasmodium under nutrient-restricted conditions. Combination of antimalarial agent 51 with the residual transport inhibitor PRT-2 can enhance the antimalarial effect. Antimalarial agent 51 can be used in the study of malaria targeting the PSAC channel .

HY-156920

VDX-111	Necroptosis RIP kinase	Inflammation/Immunology Cancer
VDX-111 is an analog of vitamin D. VDX-111 exhibits cytotoxicity in ovarian cancer cells through upregulation of RIPK1/RIPK3 pathway and induction of necroptosis. VDX-111 promotes expressions of cytokines and exhibits antitumor activity in mouse model .

HY-149031

DHODH-IN-22	Dihydroorotate Dehydrogenase	Cancer
DHODH-IN-22 is a potent, selective and orally active dihydroorotate dehydrogenase (DHODH) inhibitor with an IC₅₀ value of 0.3 nM. DHODH-IN-22 can be used for researching acute myelogenous leukemia (AML) .

HY-163538

TYM-3-98	PI3K Apoptosis	Cancer
TYM-3-98 is a selective inhibitor for PI3Kδ, with an IC₅₀ of 7.1 nM. TYM-3-98 inhibits proliferationso of B-lymphoma cells. TYM-3-98 inhibits PI3K/AKT/mTOR signaling pathway through induction of apoptosis. TYM-3-98 exhibits good pahrmacokinetic characters and antitumor efficacy in mouse/rat model, without significant toxicity .

HY-101266A

Milademetan tosylate DS-3032 tosylate	MDM-2/p53	Cancer
Milademetan tosylate is the tosylate salt form of Milademetan (HY-101266). Milademetan tosylate is an orally active inhibitor for MDM2. Milademetan tosylate arrests the cell cycle at G1 pahse, induces the apoptosis Milademetan tosylate restores the p53 activity by targeting the p53-MDM2 interaction, and exhibits anticancer activity against Merkel cell carcinoma (MCC) .

HY-170576

FLT3-IN-28	FLT3 STAT Apoptosis	Cancer
FLT3-IN-28 (Compound 12y) is an orally active FLT3 inhibitor with antitumor activity. FLT3-IN-28 selectively inhibits cancer cells harboring the FLT3 internal tandem duplication (ITD) mutation, with IC₅₀ values of 85, 290, 130, 65, and 220 nM for BaF3-FLT3-ITD, BaF3-TEL-VEGFR2, MV4-11, MOLM-13, and MOLM-14 cell lines respectively (MV4-11 and MOLM-13/14 are acute myeloid leukemia (AML) cell lines carrying the FLT3-ITD mutation). Additionally, FLT3-IN-28 can downregulate the phosphorylation levels of FLT3 and STAT5 in MOLM-13 cells and induce cell cycle arrest and Apoptosis. FLT3-IN-28 has an oral bioavailability of 19.2% in SD rats and can prolong survival in a dose-dependent manner in NSG mice xenografted with MOLM-13 cells. FLT3-IN-28 holds promise for research in cancer fields related to FLT3-ITD .

HY-181260

PRMT5-MTA-IN-8	Histone Methyltransferase Apoptosis	Cancer
PRMT5-MTA-IN-8 is an orally active PRMT5-MTA complex inhibitor (IC₅₀ = 4.4 nM). PRMT5-MTA-IN-8 inhibits the intracellular production of symmetric dimethylarginine (SDMA) as well as the proliferation of MTAP-deficient cells. PRMT5-MTA-IN-8 exerts antitumor efficacy by inhibiting PRMT5, reducing SDMA levels and inducing tumor cell apoptosis in mouse models of triple-negative breast cancer. PRMT5-MTA-IN-8 can be used in research related to cancers such as triple-negative breast cancer .

HY-183819

CRBN ligand-903-trans-1,4-cyclohexanediamine-Boc	E3 Ligase Ligand-Linker Conjugates	Cancer
CRBN ligand-903-trans-1,4-cyclohexanediamine-Boc is a cereblon (CRBN) ligand and ligase binding ligand (LBL) used in synthesis of p300 protein degraders, also designated as compound 28f. CRBN ligand-903-trans-1,4-cyclohexanediamine-Boc is tert-butyl (trans-4-(4-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)-1-methoxy-2-naphthamido)cyclohexyl)carbamate, a CRBN ligand intermediate for synthesis of degrader 28.

HY-181955

MS1129	Apoptosis DNA Methyltransferase HIF/HIF Prolyl-Hydroxylase Caspase	Cancer
MS1129 is a DNMT degrader that induces proteasomal degradation of DNMT1, DNMT3A and DNMT3B proteins. MS1129 upregulates TRAIL, DR4 and DR5 proteins, downregulates the decoy receptor DcR2, and activates TRAIL-dependent apoptosis via the HIF-1/2 and Caspase-10 pathways. MS1129 is applicable to the research of VHL-deficient clear cell renal cell carcinoma .

HY-P992074

Zemlikafusp alfa IPH6501	CD20 Interleukin Related	Cancer
Zemlikafusp alfa (IPH6501) is a tetra-specific NK cell engager that targets CD20, CD16a, NKp46 and carries an IL-2 variant. Zemlikafusp alfa (IPH6501) is used in research for the treatment of relapsed/refractory B-cell non-Hodgkin lymphoma .

HY-181427

UT-143	Androgen Receptor	Cancer
UT-143 is an orally active, selective irreversible covalent antagonist of androgen receptor (AR). UT-143 inhibits the proliferation of AR-positive prostate cancer cells, reduces the weight of androgen target tissues in rats, and suppresses the growth of AR-positive xenograft tumors. UT-143 can be used for the research of prostate cancer .

HY-181849

MS2928	Histone Methyltransferase	Cancer
MS2928 is a selective SETD8 inhibitor with an IC₅₀ of 0.14 μM against SETD8 methyltransferase activity. MS2928 reduces cellular H4K20_me1 levels and inhibits proliferation of SETD8-overexpressing multiple myeloma cells. MS2928 inhibits tumor growth in xenograft mouse models of SETD8-overexpressing multiple myeloma. MS2928 can be used for the study of SETD8 biological functions and multiple myeloma .

HY-124693

DB1055	Apoptosis	Cancer
DB1055 is a HOXA9 inhibitor that competes with HOXA9 binding to DNA (blocking its DNA interaction activity). DB1055 induces in vitro cell growth reduction, cell apoptosis, and differentiation in human acute myeloid leukemia (AML) cells. DB1055 leads to monocyte-to-macrophage differentiation and exhibits antileukemic activities in a human THP-1 AML in vivo model. DB1055 does not impact human CD34⁺ bone marrow cells. DB1055 can be used for the research of acute myeloid leukemia^[1].

HY-181789

DOT1L808	PROTACs Histone Methyltransferase	Cancer
DOT1L808 is a potent and highly selective DOT1L PROTAC degrader with a DC₅₀ value of 5 nM. DOT1L808 can promote the ubiquitination and degradation of DOT1L. DOT1L808 exhibits antitumor activity in an orthotopic leukemia model .

HY-182685

MMV693183	Acetyl-CoA synthetase Parasite	Infection
MMV693183 is an orally active inhibitor of Plasmodium falciparum acetyl-CoA synthetase (AcAS), with an IC₅₀ of 300 nM against Plasmodium falciparum. MMV693183 exhibits potent inhibitory activity against clinical isolates of malaria parasites, including Artemisinin (HY-B0094)-resistant strains. MMV693183 is metabolized in vivo into the active antimetabolite CoA-MMV693183, which exerts effects of killing asexual blood-stage parasites and blocking transmission to Anopheles mosquitoes by binding to and inhibiting the function of acetyl-CoA synthetase, thereby reducing the levels of acetyl-CoA and 4'-phosphopantetheine. In humanized mouse models, MMV693183 shows favorable in vivo efficacy, drug-like properties, and no significant cytotoxicity or off-target activity against human cells. MMV693183 is widely used in malaria-related research as a parasiticide and metabolic disruptor .

HY-P992465

SIWA318H	Fc Receptor (FcR)	Cancer
SIWA318H is an adbanvced glycation end product (AGE) specific antibody. SIWA318H selectively binds to advanced glycation end product biomarkers, human FcγRIIIa, and pancreatic cancer cells, and cancer-associated fibroblasts. SIWA318H suppresses tumor growth in mouse PSN1 xenografts. SIWA318H can be used for the research of pancreatic cancer .

HY-P991924

CO-1	CD47	Cancer
CO-1 is an IgG4 anti-CD47 antibody. CO-1 not only enhances themacrophage phagocytosis activity but also induces a unique and fast form of programmed celldeath (PCD) in cancer cells directly through ligation of CD47. CO-1 has anticancer activity against hematologic malignancies such as acute lymphoblastic leukemia .

HY-P991896

AT1412 AT14-012	Transmembrane Glycoprotein	Inflammation/Immunology Cancer
AT1412 is a CD9-binding antibody. AT1412 binds to the tetraspanin protein CD9 and modulates CD9 function by enhancing T cell adhesion to endothelial cells (HUVECs) and transendothelial migration. AT1412 binds to B-ALL cell lines but not to T-ALL. AT1412 induces antibody-dependent cellular cytotoxicity in B-ALL cell lines. AT1412 binds to melanoma cells, B-ALL, gastric cancer, colorectal cancer, and pancreatic cancer cells ^[1] .

Cat. No.	Product Name	Target	Research Area	Image